Blood Circulatory Level of Seven Sirtuins in Alzheimer’s Disease: Potent Biomarker Based on Translational Research

Rashmita Pradhan1 · Abhinay Kumar Singh2 · Pramod Kumar1 · Swati Bajpai1 · Mona Pathak3 · Prasun Chatterjee1 · Sadanand Dwivedi3 · A. B. Dey1 · Sharmistha Dey2

Received: 19 July 2021 / Accepted: 25 November 2021 / Published online: 7 January 2022 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract

Alzheimer’s disease (AD) is an accelerating neurodegenerative disorder. Dysfunction of mitochondria and oxidative stress contributes to the pathogenesis of AD. Sirtuins play a role in this pathway and can be a potential marker to study neurodegenerative changes. This study evaluated serum levels of all seven sirtuin (SIRT1–SIRT7) proteins in three study groups: AD, mild cognitive impairment (MCI) and geriatric control (GC) by surface plasmon resonance (SPR) technique. Further, it was validated by the Western blot experiment. ROC analysis was performed to differentiate the study group based on the concentration of serum SIRT proteins. Out of seven sirtuins, serum SIRT1, SIRT3 and SIRT6 levels (mean ± SD) were significantly decreased in AD (1.65 ± 0.56, 3.15 ± 0.28, 3.36 ± 0.32 ng/µl), compared to MCI (2.17 ± 0.39, 3.60 ± 0.51, 3.73 ± 0.48 ng/µl) and GC (2.84 ± 0.47, 4.55 ± 0.48, 4.65 ± 0.55 ng/µl). ROC analysis showed the cut-off value with high sensitivity and specificity for cognitive impairment (AD and MCI). The concentration declined significantly with the disease progression. No specific difference was observed in the case of other SIRTs between the study groups. This study reveals an inverse relation of serum SIRT1, SIRT3 and SIRT6 concentration with AD. ROC analysis showed that these serum proteins have greater accuracy in diagnosing of AD. This is the first report of estimation of all seven serum sirtuins and the clinical relevance of SIRT3 and SIRT6 as serum protein markers for AD.

Keywords Sirtuins · Alzheimer’s disease · Mild cognitive impairment · SPR · Protein marker

Introduction

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder, characterized by progressive loss of memory, executive function, thinking and behaviour leading to a comprehensive cognitive dysfunction. The AD symptoms progressed slowly and worsened over time, which later interfered with the activities of daily living [1]. Mild cognitive impairment (MCI) is explained as impairment of one or more cognitive domains, is the earliest stage of disease, and associated with an increased risk of AD. At present, AD is un-curable as there is no effective therapy that can delay the onset or slow AD progression. It is crucial to explore novel and effective treatment strategies for AD. There is a need to understand the fundamental molecular and cellular involvement in the disease, translating into clinical diagnosis and therapies.

The neuropathological hallmark of AD comprises of extracellular aggregation of β-amyloid peptide and intracellular precipitations of insoluble protein aggregates of phosphorylated microtubule-associated tau protein. It is also pathologically characterized by oxidative stress, mitochondrial damage, altered mitochondrial distribution, neuroinflammation, calcium deregulation, metal dishomeostasis, neurofibrillary tangle formation and amyloid-β (Aβ) oligomerization and fibrillation [2]. Neurodegeneration in AD leads to a significant increase in neuronal ROS production [3]. Factors such as cell senescence, oxidative stress and ageing are all crucial factors in the pathogenesis of AD [4].

© Rashmita Pradhan biorashmita@gmail.com
© Sharmistha Dey sharmistha_d@hotmail.com

1 Department of Geriatric Medicine, AIIMS, Ansari Nagar, New Delhi 110029, India
2 Department of Biophysics, AIIMS, Ansari Nagar, New Delhi 110029, India
3 Department of Biostatistics, AIIMS, New Delhi, India

Springer
Amyloidosis can also promote AD by the alteration of ECM components [5]. ECM is composed of various types of proteins and proteoglycans which provides complex and dynamic support to cells and maintained tissue homeostasis. Recently it was studied that cell-derived ECM has the capacity to proliferate, differentiate and maintain native phenotype of podocyte cell in in vitro condition [6], which strengthens the role of ECM in morphological and functional regulation of neurons.

Many studies have shown the potential role of sirtuins in ageing and age-related diseases such as AD and other neurodegenerative disorders. The animal and cell culture models showed that SIRT1 plays a neuroprotective role in the brain. A significant reduction in RNA and protein expression levels of SIRT1 in parietal cortex of post-mortem AD patients' brains compared to controls is reported in the literature. Accumulation of amyloid-beta and tau in the cerebral cortex of AD patients is strongly associated with the loss of SIRT1 [7]. In our previous study, SIRT1 was downregulated in the blood of AD patients compared to normal older subjects [8]. A study has found an association between AD susceptibility and a polymorphism in an intron of SIRT2 gene [9].

SIRT3 is present in the mitochondrial matrix. Mitochondria is the main source of ROS and energy production within neurons and thus is the critical mediator of age-related diseases such as neurodegeneration [10]. Mitochondrial ROS production increases in the brains of aged mice [11]. Similarly, there is a progressive trend towards a pro-oxidant state as human’s age; thus, ROS increases with age [12]. Progressive ROS accumulation in neurons poses a significant threat, leading to exacerbated protein aggregation, cell death and the onset of the pathogenesis of AD, as well as several other neurodegenerative diseases [13, 14]. The overexpression of SIRT1 and SIRT3 reduced ROS generation, thereby preventing neuronal death [15, 16]. Absence of SIRT3 causes hyperacetylation of SOD2 (Superoxide dismutase2) and Cyp-D (Cyclophilin D) [17]. Both SIRT1 and SIRT3 levels were found to reduce in the entorhinal cortex and hippocampal sub-regions in the post-mortem human AD brain [18, 19]. SIRT3 regulates mitochondrial function and highly expressed in the brain [20]. It also mediated antioxidant and metabolic effects, which results in enhanced neuronal survival. Overexpression of SIRT3 and SIRT1 protects neurons from cellular stresses and ROS formations [15, 21], mitochondrial dysfunction and apoptosis [22]. Calorie restriction reduced neurodegeneration by up-regulating SIRT3 [23] in AD and PD animal models. SIRT3 and SIRT6 expressions change the ageing brain in a region-specific manner [24, 25]. SIRT3 is also expressed in the tissues of kidney, heart, liver, adipose tissue and brain [26].

SIRT6 is present in the nucleus known as a longevity gene. It is a NAD-dependent histone deacetylase that has various roles such as telomere maintenance, DNA repair, genome integrity, energy metabolism, inflammation and life span regulation [27]. Accumulation of senescent cells in ageing due to the defective DNA repair and accumulation replication is one of the causes of neurodegenerative diseases such as AD. SIRT6 were deficit in aged mice brain [24] and damaged DNA [28]. It is also downregulated in post-mortem brains of AD patients compared to cognitively normal subjects. It was found that Aβ42 significantly decreased SIRT6 expression, which was associated with a decreased level of p53 [29].

A study on a brain-specific SIRT6–knockout (SIRT6KO) mouse model found that it exhibited accelerated ageing and causes pathological changes in behaviour, presented with accumulated DNA damage, and increased apoptosis and hyperphosphorylated Tau levels. There was an increase in Tau stability and phosphorylation through GSK3 activation when SIRT6 depleted in cells. These findings indicate that SIRT6 protects the brain from naturally accumulating DNA damage, protecting against neurodegeneration [30]. The potential roles of SIRT6 in AD have remained unexplored. SIRT4, SIRT5 and SIRT7 showed to have different roles in various tissues, but their role in brain was not explored.

Identification of biomarker molecules in blood would be more widely applicable than cerebrospinal fluid (CSF) due to being noninvasive, less expensive and very rapid. Sirtuin protein may be the next target for AD for early diagnosis. Based on several findings on involvement of sirtuin proteins in neurodegenerative diseases and evidence from our previous work, this study focused on quantifying all sirtuins in blood of AD, MCI and GC to identify a specific sirtuin to establish it as a potential blood-based marker for AD.

Methods

Study Participants

A total of 138 subjects were recruited for the present study. All participants underwent clinical testing, biochemical testing and cognitive assessment at the Memory Clinic, Department of Geriatric Medicine of the All-India Institute of Medical Sciences, New Delhi, India. The Ethics Committee of AIIMS approved the study protocol (IESC/T-28/03.01.2014). After providing informed consent, each participant completed a brief questionnaire about their medical history, health behaviours such as addiction, demographic, education profile, occupation, living status, co-morbidities and disease duration. Among them, 47 patients diagnosed with AD, 43 patients with MCI and 48 subjects were geriatric controls (GC). All were diagnosed as per the existing diagnostic criteria by the team of geriatricians and a neuropsychologist. All participants with MCI met Petersen’s 2011 criteria: (1) concern about their cognitive deficit
in comparison to their previous level; (2) performance that is lower than their age- and education-matched normative; (3) no or minimal impairment in their basic and instrumenta\_\_\_\_\_\_\_tional activities of daily living (ADL); and (4) not meeting DSM-V-2013 criteria for dementia. A basic protocol was completed, which included the HMSE, Barthel Activities of Daily Living (BADL), Instrumental Activities of Daily Living (IADL) and Geriatric Depression Scale (GDS).

Older subjects above 60 years of age, with no reported major systemic or psychiatric illness, were recruited as geriatric controls (GC). All the volunteers and informants who accompanied the patients to the Outpatient Geriatric Department gave the consent. Further, any participant with delirium or any chronic systemic illness and major psychiatric diseases were not included in the study. All possible reversible clinical causes were ruled out at the diagnosis by the geriatrician. HMSE scores considered for these three groups were normal: 26 and above, MCI: 17–25 and AD: less than 17. AD was diagnosed as per NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria) [31]. The normal control group consists of subjects with no apparent or disability and HMSE score of 26 or more. Further, each case underwent imaging evaluation of magnetic resonance imaging (MRI) of the brain and positron emission tomography (PET) scan of Tau and fluorodeoxyglucose (FDG).

**Estimation of Serum Sirtuin Levels**

Two millilitres of venous blood samples was collected from all subjects and was allowed to stand for 1 h. Serum samples were extracted after centrifugation at 3000 rpm for 10 min and stored in aliquots at −80 °C until the time of experimental work.

**By SPR Technology**

SPR was used for estimation of serum proteins, using the BIACore-3000 (Wipro GE Healthcare, Sweden), a biosensor-based system for real-time monitoring of specific interaction analysis. Primary antibodies mouse anti-human SIRT1 monoclonal IgG (Santa Cruz Biotechnology), goat anti-human SIRT2 polyclonal IgG (Santa Cruz Biotechnology), rabbit anti-human SIRT3 polyclonal IgG (Santa Cruz Biotechnology), rabbit anti-human SIRT4 polyclonal IgG (Santa Cruz Biotechnology), mouse anti-human SIRT5 monoclonal IgG (Santa Cruz Biotechnology), rabbit anti-human SIRT6 polyclonal IgG (Sigma) and rabbit anti-human SIRT7 polyclonal IgG were immobilized on different flow cells of a CM5 sensor chip via amine coupling kit (Wipro GE Healthcare, Sweden). To prepare the standard curve, six different known concentrations of the purified recombinant proteins of SIRT1 (0, 3.18, 5.31, 10.62, 15.94, 21.25 ng/µl), SIRT2 (0, 1.94, 3.42, 6.84, 11.42 ng/µl), SIRT3 (0, 2.1, 4.2, 6.4, 8.5, 10.7 ng/µl), SIRT4 (0, 1.40, 4.21, 8.43, 11.25, 14.06 ng/µl), SIRT5 (0, 2.7, 4.5, 6.3, 9.12 ng/µl), SIRT6 (0, 2.14, 4.28, 6.42, 8.56, 10.7 ng/µl) and SIRT7 (0, 1.55, 3.87, 5.42, 7.75, 11.62 ng/µl) passed over the respective immobilized antibodies on the sensor chip and obtained RU values.

The serum was passed over the immobilized antibodies. For each sample, the RU value was recorded and the serum concentration of sirtuins in different subjects was derived from the standard curves.

**By Western Blot**

For further validation, the expression level of proteins in serum was performed by Western blot experiment. Albumin was removed from Albumin out kit (G-Biosciences) according to the manufacturer’s protocol, followed by BCA (Pierce™ BCA Protein Assay Kit) to determine the concentration of serum proteins. The standard curve was plotted using different dilutions of BSA (Bovine Serum Albumin). The samples were diluted empirically such that the approximate concentration of the protein would fall in the linear range of the standard curve. Diluted samples were mixed with 200 µl working BCA (bicinchoninic acid) reagent in 96-well plates and incubated for 30 min at 37 °C. At 562 nm, the absorbance was measured by an ELISA (enzyme-linked immunoassay) reader. The protein concentrations of the samples were calculated from the standard curve. Randomly, three samples were selected from each group and 30 µg of total protein was loaded on 10% SDS–PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis), then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore Membrane Technologies) and was blocked with 5% nonfat dry milk (NFM) which was made in TBS (10 mM Tris pH 7.5, 150 mM NaCl), and incubated for 2 h at room temperature and after that incubated with primary antibodies which were diluted with TBS, containing 1% NFM at 4 °C overnight. The following primary antibodies were used: mouse anti-human SIRT1 monoclonal IgG (1:300), rabbit anti-human SIRT3 polyclonal IgG (1:500) and rabbit anti-human SIRT6 polyclonal IgG (1:2000). Then, washing was done with TBS-T (20 mM Tris pH7.5, 500 mM NaCl, 0.05% Tween 20) and membranes were incubated with HRP-conjugated secondary antibodies goat anti-mouse IgG (1:5000, Santa Cruz Biotechnology, USA), goat anti-rabbit IgG (1:4000, Santa Cruz Biotechnology, USA) and goat anti-rabbit IgG (1:4000, Santa Cruz Biotechnology, USA) at room temperature for 1 h. After washing with TBS-T, the PVDF membranes were visualized by an enhanced chemiluminescent system (Pierce ECL Western Blotting Substrate, Thermo Scientific, Rockford, IL) and my Image Analysis Software (Thermo scientific) was used to observe the density of bands.
Statistical Analysis

Statistical analyses were performed in Stata/SE version 9 and Graphpad prism5 (College Station, TX, USA, and GraphPad Software, Inc, La Jolla, USA). Descriptive analysis was done and presented with mean and standard deviation for all variables. Two groups were compared by using the chi-square test for categorical variables and Student’s t test for continuous variables. Three groups (AD, MCI and GC) were compared for continuous variables by using one-way ANOVA followed by post hoc comparison using the Bonferroni test. Correlation between two continuous variables was assessed using the Cary Pearson correlation coefficient. Receiver operating characteristics (ROC) analysis was performed for detecting optimum diagnostic cut-off value of sirtuin proteins. Analysis of covariance was done to check the difference in the levels of sirtuins between controls (GC) and patients (AD, MCI) after adjusting age, gender, education, occupation and duration. The p-value of <0.05 was considered as statistical tests were significant.

Result

Demographic and Clinical Data

Descriptive analysis of various demographic and clinical parameters of study subjects is presented in Table 1 and Table 2. The age of each study group (AD, MCI and GC) was categorized into three subgroups: 60–65 years, 66–75 years and ≥ 76 years. The mean ages of AD, MCI and GC subjects were 70.74, 68.62 and 68.23, respectively. Mean HMSE scores were 13.63, 22.44 and 28.31 in AD, MCI and GC groups, respectively. With respect to sex, age category, location, education, addiction, family history of AD and number of co-morbidities, there were no significant differences between groups, while significant differences were observed with respect to occupation, duration of disease, BADL, hypertension, joint disease, MTA score and parietal score between all three groups. With the increase duration of the disease, the incidence of cognitive impairment also increases and was significant among the groups (p < 0.0001).

Table 1 Demographic data of AD, MCI and GC study subjects

| Variable                   | Total subjects | AD     | MCI    | GC     | p value |
|----------------------------|----------------|--------|--------|--------|---------|
| N                          | 138            | 47     | 43     | 48     |         |
| Sex                       |                |        |        |        |         |
| Male, n (%)                | 102 (73.91)    | 32 (66.67) | 34 (79.07) | 36 (76.60) | 0.354   |
| Female, n (%)              | 36 (26.09)     | 16 (33.33) | 9 (20.93)  | 12 (23.4)  |         |
| Age category, n (%)        |                |        |        |        |         |
| 60–65 years                | 46 (33.33)     | 11 (23.4)  | 18 (41.86) | 17 (35.42) | 0.355   |
| 66–75 years                | 66 (47.83)     | 24 (51.06) | 19 (44.19) | 23 (47.92) |         |
| ≥ 76 years                 | 26 (18.84)     | 12 (25.53) | 6 (13.95)  | 8 (16.67)  |         |
| Age (mean ± SD)            |                | 70.74 ± 7.02 | 68.62 ± 7.23 | 68.23 ± 5.78 | 0.277   |
| Urban (n, %)               | 73 (53.28)     | 26 (56.52) | 25 (58.14) | 22 (45.83) | 0.434   |
| Rural (n,% )               | 64 (46.72)     | 20 (43.48) | 18 (41.86) | 26 (54.17) |         |
| Education ((years) n, %)   |                |        |        |        |         |
| Illiterate (0)             | 18 (13.04)     | 5 (10.64)  | 7 (16.28)  | 6 (12.5)   | 0.482   |
| Primary (class 1–5th)      | 29 (21.1)      | 9 (19.15)  | 10 (23.26) | 10 (20.83)|         |
| Secondary (class 6th–12th) | 48 (34.78)     | 19 (40.43) | 14 (32.56) | 15 (31.25)|         |
| Graduate and above (≥ 13th)| 43 (31.16)     | 14 (29.78) | 12 (27.9)  | 17 (35.42)|         |
| Occupation                 |                |        |        |        |         |
| Unemployed                 | 35 (25.37)     | 13 (17.66) | 7 (16.28)  | 15 (31.25)| 0.0001  |
| Employed                   | 5 (3.62)       | 0 (0)    | 0 (0)   | 5 (10.42)|         |
| Retired                    | 63 (45.65)     | 24 (51.06) | 19 (44.19) | 20 (41.67)|         |
| Business or farming        | 35 (25.36)     | 10 (21.28) | 17 (39.53) | 8 (16.67) |         |
| Addiction                  |                |        |        |        |         |
| Yes                        | 40 (29.20)     | 19 (40.43) | 11 (25.58) | 11 (22.92)| 0.184   |
| No                         | 97 (70.80)     | 28 (59.57) | 32 (74.42) | 37 (77.08)|         |
The concentrations of sirtuins in serum were determined from the standard curves using RU obtained from the binding of serum over the sirtuin antibodies. The immobilized protein concentration of 1 pg/mm² corresponds to one RU. Out of seven sirtuins concentration of serum SIRT1, SIRT3 and SIRT6 was found in GC group (SIRT1: 2.84 ± 0.06 ng/µl, 95% CI: 2.70–2.97 ng/µl), (SIRT3: 4.55 ± 0.15 ng/µl, 95% CI: 4.42–4.69 ng/µl), (SIRT6: 4.64 ± 0.55 ng/µl, 95% CI: 4.48–4.81 ng/µl) significantly higher than MCI group (SIRT1: 2.17 ± 0.06 ng/µl, 95% CI: 2.05–2.29 ng/µl), (SIRT3: 3.60 ± 0.51 ng/µl, 95% CI: 3.45–3.76 ng/µl), (SIRT6: 3.72 ± 0.48 ng/µl, 95% CI: 3.58–3.88 ng/µl), and AD group (SIRT1: 1.65 ± 0.08 ng/µl, 95% CI: 1.48–1.82 ng/µl), (SIRT3: 3.15 ± 0.28 ng/µl, 95% CI: 3.07–3.24 ng/µl), (SIRT6: 3.37 ± 0.34 ng/µl, 95% CI: 3.26–3.45 ng/µl) (Fig. 1).
Serum sirtuin levels of other four sirtuins in mean ± SD:

SIRT2 (GC — 11.28 ± 1.71 ng/µl, 95% CI: 10.79–11.78 ng/µl; MCI — 11.76 ± 1.94 ng/µl, 95% CI: 11.16–12.36 ng/µl; AD — 11.33 ± 1.62 ng/µl, 95% CI: 10.85–11.80 ng/µl; AD vs GC p = 0.897, AD vs MCI p = 0.2507, MCI vs GC p = 0.2145).

SIRT4 (GC — 2.66 ± 1.16 ng/µl, 95% CI: 2.33–3.00 ng/µl; MCI — 3.49 ± 0.66 ng/µl, 95% CI: 3.29–3.70 ng/µl; AD — 2.56 ± 0.76 ng/µl, 95% CI: 2.34–2.78 ng/µl; AD vs GC p = 0.6133, AD vs MCI p < 0.0001, MCI vs GC p = 0.0001).

SIRT5 (GC — 1.25 ± 0.44 ng/µl, 95% CI: 1.12–1.37 ng/µl; MCI — 1.22 ± 0.45 ng/µl, 95% CI: 1.08–1.37 ng/µl; AD — 2.18 ± 0.59 ng/µl, 95% CI: 2.01–2.35 ng/µl; AD vs GC p < 0.0001, AD vs MCI p < 0.0001, MCI vs GC p = 0.8069).

SIRT7 (GC — 2.31 ± 0.63 ng/µl, 95% CI: 2.13–2.49 ng/µl; MCI — 1.81 ± 0.37 ng/µl, 95% CI: 1.69–1.93 ng/µl; AD — 1.87 ± 0.49 ng/µl, 95% CI: 1.73–2.02 ng/µl; AD vs GC p < 0.0003, AD vs MCI p = 0.5114, MCI vs GC p < 0.0001).

Hence, SIRT2, SIRT4, SIRT5 and SIRT7 were not significant among different groups (Fig. 1).

In the analysis of covariance, after adjustment of occupation, duration of disease, joint disease and comorbidities between the three groups, the serum protein levels of SIRT1, SIRT3 and SIRT6 were found to be significantly lower (p < 0.0001) in the case of the AD group as compared to the MCI (p < 0.0001) and GC groups (p < 0.0001). The values of all three proteins were significantly different among the three categories (Table 3). A significant difference was observed in serum protein concentration with respect to age, sex, education, duration of disease, occupation, joint disease, HTN and DM in different groups (Table 4).

ROC analysis was carried out based on SPR data to measure the utility of SIRT1, SIRT3 and SIRT6 out of seven sirtuins as protein markers for AD and MCI (Fig. 2). The threshold for detecting AD and MCI was selected based on the distribution of specificities and sensitivities. In the case
of SIRT1, the area under curve (AUC) for distinguishing AD vs GC was 0.9275 (cut-off — 2.31 ng/μl; sensitivity — 93.75%; specificity — 87.23%), AUC for distinguishing MCI vs GC was 0.8697 (cut-off — 2.52 ng/μl; sensitivity — 79.17%; specificity — 76.74%) and AUC for distinguishing AD vs MCI was 0.7905 (cut-off — 1.90 ng/μl; sensitivity — 76.74%; specificity — 74.47%). For SIRT3, the area under curve (AUC) for distinguishing AD vs GC was 0.9969 (cut-off — 3.68 ng/μl; sensitivity — 97.92%; specificity — 95.74%), AUC for distinguishing MCI vs control was 0.9169 (cut-off — 3.99 ng/μl; sensitivity — 91.67%; specificity — 79.07%) and AUC for distinguishing AD vs MCI was 0.7840 (cut-off — 3.33 ng/μl; sensitivity — 74.42%; specificity — 78.72%). Similarly, in the case of SIRT6, the AUC for distinguishing AD vs GC was 0.9818 (cut-off — 3.97 ng/μl; sensitivity — 93.75%; specificity — 93.62%), AUC for distinguishing MCI vs control was 0.8970 (cut-off — 4.1 ng/μl; sensitivity — 81.25%; specificity — 76.74%) and AUC for distinguishing AD vs MCI was 0.7288 (cut-off — 3.45 ng/μl; sensitivity — 74.42%; specificity — 68.09%). This result shows that lower serum SIRT1, SIRT3 and SIRT6 levels can be a distinctive marker of AD.

Pearson correlation analyses evaluated the correlation between protein concentrations (SIRT1, SIRT3 and SIRT6) and HMSE score. We found that lower HMSE scores were associated with lower concentration of proteins with significant positive correlation (Pearson correlation coefficient for SIRT1 \( r = 0.294 \), \( p \)-value < 0.0010, SIRT3 \( r = 0.373 \), \( p \)-value < 0.0001 and for SIRT6 \( r = 0.307 \), \( p \)-value < 0.0001) (Fig. 3). With respect to age, sex, years of education and duration of disease, no significant difference was observed in serum sirtuin concentration among AD, MCI and GC subjects.

### Table 3

| Protein | Unadjusted/adjusted | GC       | MCI      | AD       | \( p \) value | Post hoc comparison | \( p \) value |
|---------|---------------------|----------|----------|----------|--------------|---------------------|--------------|
| SIRT1   | Unadjusted          | 2.84 ± 0.06 | 2.17 ± 0.06 | 1.654 ± 0.08 | 0.0001 | NC/MCI | 0.0001 |
|         | Adjusted            | 2.92 ± 0.14 | 2.26 ± 0.24 | 1.52 ± 0.27 | 0.0001 | NC/AD | 0.0001 |
|         |                     |          |          |          |              | MCI/AD | 0.0001 |
| SIRT3   | Unadjusted          | 4.55 ± 0.15 | 3.60 ± 0.51 | 3.15 ± 0.28 | 0.0001 | NC/MCI | 0.0001 |
|         | Adjusted            | 4.42 ± 0.15 | 4.02 ± 0.46 | 2.83 ± 0.24 | 0.0001 | NC/AD | 0.0001 |
|         |                     |          |          |          |              | MCI/AD | 0.0020 |
| SIRT6   | Unadjusted          | 4.64 ± 0.55 | 3.72 ± 0.48 | 3.37 ± 0.34 | 0.0001 | NC/MCI | 0.0001 |
|         | Adjusted            | 4.67 ± 0.13 | 4.14 ± 0.42 | 2.83 ± 0.32 | 0.0001 | NC/AD | 0.0001 |
|         |                     |          |          |          |              | MCI/AD | 0.0300 |

Adjusted for occupation, duration of disease, joint disease and no. of co-morbidities

### By Western Blot

Western blot analysis of serum samples was used to validate differential expression of SIRT1, SIRT3 and SIRT6 in AD, MCI and GC groups obtained by SPR data. The result showed a low band density of SIRT1, SIRT3 and SIRT6 proteins in AD and MCI patients compared to GC subjects, as observed in SPR data (Fig. 4).

### Discussion

Dementia and specifically AD in older people represent a booming public health problem. AD is one of the most commonly underestimated and under-diagnosed geriatric syndromes in India. It is challenging for early diagnose AD and MCI due to distinct and subjective clinical features. There is no definitive treatment for AD, which implies that the conditions need to be detected early to stop further dependence. Most of the molecules failed to prove them as a potent blood-based biomarker because of the lack of sensitivity and specificity. Several promising research are under process which includes brain imaging, cerebrospinal fluid proteins and substances in blood towards establishing biomarkers for dementia, especially AD, but none showed a promising marker for early clinical diagnosis.

Previous studies have analysed serum levels of SIRT1 and SIRT3 protein with ageing and found that the expression was downregulated with age \[8, 32\]. SIRT2, SIRT4, SIRT5 and SIRT7 are largely unexplored for neurodegenerative diseases and the brain. These proteins are new therapeutic targets for neurodegenerative diseases in recent time due to a critical role in the nervous system. With this goal, we are here for...
| Category               | Subcategory               | SIRT1 AD (Mean ± SD) | SIRT1 MCI (Mean ± SD) | SIRT1 p-value | SIRT3 AD (Mean ± SD) | SIRT3 MCI (Mean ± SD) | SIRT3 p-value | SIRT6 AD (Mean ± SD) | SIRT6 MCI (Mean ± SD) | SIRT6 p-value |
|------------------------|---------------------------|----------------------|-----------------------|---------------|----------------------|-----------------------|---------------|----------------------|-----------------------|---------------|
| Age (years)            | 60–65                     | 1.88 ± 0.67          | 2.20 ± 0.41           | 3.20 ± 0.54   | 0.0001               | 3.04 ± 0.23          | 3.46 ± 0.53   | 4.50 ± 0.37          | 0.0001               | 3.21 ± 0.22   |
|                        | 66–75                     | 1.56 ± 0.52          | 2.12 ± 0.39           | 2.65 ± 0.31   | 0.0001               | 3.16 ± 0.39          | 3.66 ± 0.52   | 4.51 ± 0.55          | 0.0001               | 3.27 ± 0.33   |
|                        | ≥ 76                      | 1.62 ± 0.51          | 2.21 ± 0.39           | 2.59 ± 0.15   | 0.0001               | 3.34 ± 0.28          | 3.45 ± 0.84   | 4.54 ± 0.46          | 0.0001               | 3.7 ± 0.44    |
| Gender                 | Male                      | 1.58 ± 0.56          | 2.13 ± 0.42           | 2.82 ± 0.49   | 0.0001               | 3.21 ± 0.36          | 3.56 ± 0.59   | 4.54 ± 0.47          | 0.0001               | 3.38 ± 0.39   |
|                        | Female                    | 1.87 ± 0.51          | 2.3 ± 0.23            | 2.86 ± 0.44   | 0.7136               | 3.0 ± 0.23           | 3.55 ± 0.37   | 4.47 ± 0.47          | 0.0001               | 3.19 ± 0.22   |
| Duration of disease    | <2 years                  | 1.66 ± 0.53          | 2.15 ± 0.38           | 2.92 ± 0.48   | 0.0001               | 3.23 ± 0.32          | 3.56 ± 0.52   | 4.51 ± 0.44          | 0.0001               | 3.12 ± 0.29   |
|                        | ≥ 2 years                 | 1.49 ± 0.54          | 1.91 ± 0.39           | 2.76 ± 0.46   | 0.0016               | 2.97 ± 0.34          | 3.52 ± 0.78   | -                   | 0.0052               | 3.43 ± 0.36   |
| Education (years)      | 0                         | 1.93 ± 0.51          | 2.13 ± 0.43           | 2.88 ± 0.30   | 0.0039               | 3.11 ± 0.15          | 3.74 ± 0.38   | 4.30 ± 0.35          | 0.0001               | 3.31 ± 0.15   |
|                        | 1–12                      | 1.60 ± 0.54          | 2.25 ± 0.32           | 3.08 ± 0.56   | 0.0001               | 3.25 ± 0.38          | 3.42 ± 0.55   | 4.55 ± 0.53          | 0.0001               | 3.43 ± 0.36   |
|                        | ≥ 13                      | 1.35 ± 0.53          | 2.08 ± 0.38           | 2.75 ± 0.45   | 0.0001               | 2.99 ± 0.26          | 3.75 ± 0.66   | 4.64 ± 0.39          | 0.0001               | 3.22 ± 0.42   |
| Occupation             | Unemployed                | 1.73 ± 0.53          | 2.27 ± 0.24           | 3.05 ± 0.41   | 0.0007               | 3.11 ± 0.15          | 3.74 ± 0.38   | 4.30 ± 0.35          | 0.0001               | 3.08 ± 0.12   |
|                        | Retired                   | 1.53 ± 0.53          | 2.10 ± 0.45           | 2.61 ± 0.24   | 0.0001               | 3.25 ± 0.38          | 3.42 ± 0.55   | 4.55 ± 0.53          | 0.0001               | 3.15 ± 0.38   |
|                        | Business and farming      | 2.02 ± 0.76          | 2.33 ± 0.34           | 2.74 ± 0.39   | 0.0318               | 2.99 ± 0.26          | 3.75 ± 0.66   | 4.64 ± 0.39          | 0.0002               | 3.28 ± 0.35   |
| Joint disease          | No                        | 1.65 ± 0.58          | 2.18 ± 0.38           | 2.78 ± 0.41   | 0.0001               | 3.16 ± 0.29          | 3.56 ± 0.57   | 4.53 ± 0.52          | 0.0001               | 3.35 ± 0.77   |
|                        | Yes                       | 1.67 ± 0.27          | 1.85 ± 0.48           | 3.01 ± 0.63   | 0.0021               | 3.25 ± 0.94          | 3.44 ± 0.13   | 4.44 ± 0.23          | 0.0001               | 3.34 ± 0.35   |
| HTN                    | No                        | 1.68 ± 0.55          | 2.27 ± 0.49           | 2.82 ± 0.44   | 0.0001               | 3.14 ± 0.32          | 3.60 ± 0.50   | 4.51 ± 0.47          | 0.0001               | 3.43 ± 0.44   |
|                        | Yes                       | 1.60 ± 0.57          | 2.10 ± 0.28           | 2.87 ± 0.59   | 0.0001               | 3.18 ± 0.37          | 3.50 ± 0.62   | 4.51 ± 0.46          | 0.0001               | 3.25 ± 0.26   |
| DM                     | No                        | 1.65 ± 0.51          | 2.16 ± 0.43           | 2.83 ± 0.49   | 0.0001               | 3.17 ± 0.31          | 3.55 ± 0.56   | 4.48 ± 0.47          | 0.0001               | 3.47 ± 0.57   |
|                        | Yes                       | 1.66 ± 0.79          | 2.18 ± 0.26           | 2.89 ± 0.26   | 0.0045               | 3.13 ± 0.44          | 3.56 ± 0.59   | 4.81 ± 0.34          | 0.0001               | 3.29 ± 0.25   |
the first time quantified serum levels of seven sirtuin proteins in AD and MCI patients and compared them with GCs.

In the present study, subjects were more in the age category of 66–75 years. As per the literature, a cognitive decline and the transformation into dementia becomes more progressive during this stage. Male subjects were more dominant than female subjects in our study, which may be due to the social context and lower economic status. Evaluation methods such as a clinical score — HMSE — and an imaging score — MRI — were independently assessed for the study groups (AD, MCI, GC) and found significant ($p < 0.0001$) with the disease. We have used standard cut-offs (26 and above) for HMSE scores for our subjects in our setup. The 50% out of total subjects were normal using HMSE, a highly sensitive scoring system in detecting a cognitive decline in our setup. All subjects were classified by using structural imaging (MRI) using MTA scores, and the values were statistically significant among the groups.

This study explored the association of serum protein level that changes with AD, MCI patients and GC subjects. Pairwise comparisons between the three groups showed significantly lower SIRT1, SIRT3 and SIRT6 protein expression in AD patients than in MCI and GC subjects ($p < 0.0001$, $p < 0.0001$ and $p < 0.0001$, respectively). ROC curves for SIRT1, SIRT3 and SIRT6 protein levels were plotted separately and showed reasonably good sensitivity and specificity at the cut-off value for detecting AD and MCI patients compared to GC subjects. A significant correlation ($p < 0.0001$) existed between serum SIRT1, SIRT3 and SIRT6 concentration with HMSE scores. A positive correlation of protein with the HMSE score indicates that these serum protein levels decrease with poorer cognitive impairment (HMSE score).

The previous literature supports our present finding, which correlates these proteins and their involvement in AD pathology. A comparative immunoblotting and immune histochemical study of SIRT1, SIRT3 and SIRT5 in the AD brain grouped according to Braak and Braak stages of neurofibrillary degeneration in a study. The decrease in SIRT1 expression in neuronal subcellular redistribution with stepwise loss of neuroprotection dependent on the neuronal population and SIRT1 and SIRT3 decrease simultaneously with AD progression and the stage/duration of the disease [7, 18], while expression of SIRT5 increases during the progression of AD [18].

Fig. 2 ROC analysis showing the AUC for SIRT1 (a), SIRT3 (b) and SIRT6 (c) to distinguish AD vs GC, MCI vs GC and AD vs MCI.
It was reported that SIRT3 decreases in AD [18, 33]. A study in mice showed up-regulation of SIRT3 mRNA that followed the spatial and temporal profiles of Aβ accumulation [34]. In the temporal cortex of AD patients, a higher level of SIRT3 mRNA was found [35].

SIRT6 depletion causes DNA damage and ageing, reported in a recent study [36]. SIRT6 loss led to tau hyperphosphorylation via the increase in GSK3 activity, with the latter restored with SIRT6 re-expression. SIRT6 levels are reduced in human AD brain samples and mouse models [28]. These studies suggested that decrease in SIRT6 expression during AD may further enhance neuronal death and degeneration.

In our study, ROC results indicate that serum SIRT1, SIRT3 and SIRT6 have great potential to be diagnostic protein markers for AD for its accuracy in the study group. This is the first study to report the circulatory level of all seven sirtuins in serum of AD, MCI and GC subjects and the clinically diagnostic relevance of SIRT3 and SIRT6 as serum protein markers for Alzheimer’s disease.

Conclusion

For the first time, in the present study, we detected and evaluated all serum sirtuin concentrations in AD, MCI and GC patients to explore the clinical relevance. SIRT1, SIRT3 and SIRT6 protein expressions in serum were significantly low in AD compared to those in MCI and GC subjects. These protein markers can be potential sensitive diagnostic markers of AD.

A strong inverse correlation between SIRT1, SIRT3 and SIRT6 with cognition (HMSE) was identified in the study groups. These results suggest that SIRT1, SIRT3 and SIRT6 may be novel blood-based markers for AD. This study may open up the new vision of blood-based biomarkers for clinical practice and a therapeutic target for AD.

Future Prospective

A larger sample size and longitudinal studies are required to validate the potential role of serum sirtuin levels in AD.
Acknowledgements The authors acknowledged all the study participants and Indian Council of Medical Research for proving the fellowship to Rashmita Pradhan.

Author Contribution RP: major part of the experiment and wrote the manuscript, AKS: run the sample in Biacore, PK, PC, ABD, SB: diagnosed the patients and provided blood samples; MP, SND: performed statistical analysis, SD: concept and design of work, wrote and edited the manuscript.

Funding This work was supported by All India Institute of Medical Sciences, New Delhi, providing funds for procurement of equipment and consumables.

Data Availability All materials used in this study will be made available.

Code Availability Not applicable.

Declarations

Ethics Approval All India Institute of Medical Sciences Ethics Committee (AIIMS) approved the study protocol (IESC/T-28/03.01.2014).

Consent to Participate Informed consent in writing was obtained from the controls, patients or their attendants (if a patient is incapable of making signature).

Consent for Publication The manuscript contains no individual person’s data in any form.

Competing Interests The authors declare no competing interests.

References

1. Alzheimer's Association, 2016. What is Alzheimer’s? http://www.alz.org/alzheimers_disease_what_is_alzheimersasp.
2. Caldeira GL, Ferreira IL, Rego AC (2013) Impaired transcription in Alzheimer’s disease: key role in mitochondrial dysfunction and oxidative stress. J Alzheimers Dis 34(1):115–131
3. Simonian N, Coyle JT (1996) Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36(1):83–106
4. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical ageing in Alzheimer’s disease. Trends Neurosci 18(4):172–176. https://doi.org/10.1016/0166-2236(95)93897-7
5. Lepelletier F-X, Mann DMA, Robinson AC, Pinteaux E, Boutin H (2017) Early changes in extracellular matrix in Alzheimer's disease. Neuropharmacology 43(2):167–182

6. Satyam A, Tsokos MG, Tresbach JS, Zeugolis DL, Tsokos GC (2020) Cell-derived extracellular matrix-rich biomimetic substrate supports podocyte proliferation, differentiation, and maintenance of native phenotype. Adv Fucn Mater 30(44):1–22

7. Julien C, Tremblay C, Émond V, Lebbadi M, Salem N Jr, Bennett DA, Calon F (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer's disease. J Neurophysiol Exp Neurol 68(1):48–58

8. Kumar R, Chatterjee P, Sharma PK, Singh AK, Gupta A, Gill K, Tripathi M, Dey AB, Dey S (2013) Sirtuin 1: a promising serum protein marker for early detection of Alzheimer’s disease. PLoS one. 8(4):e61560

9. Wei W, Xu X, Li H, Zhang Y, Han D, Wang Y, Yan W, Wang X, Zhang J, Liu N, You Y (2014) The SIRT2 polymorphism rs10410544 and risk of Alzheimer’s disease: a meta-analysis. NeuroMol Med 16(2):448–456

10. Singh KK (2006) Mitochondria damage checkpoint, aging, and cancer. Ann N Y Acad Sci 1067(1):182–190

11. Sawada M, Carlson JC (1987) Changes in superoxide radical and lipid peroxide formation in the brain, heart and liver during the lifetime of the rat. Mech Ageing Dev 41(1–2):125–137

12. Rebrin I, Sohal RS (2008) Pro-oxidant shift in glutathione redox state during aging. Adv Drug Deliv Rev 60(13–14):1545–1552

13. Du L, Zhang X, Han Y, Burke NA, Kochanek PM, Watkins SC, Graham SH, Carcillo JA, Szabó C, Clark RS (2016) Mitochondrial poly (ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 282(20):18426–18433

14. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795

15. Shekhar S, Yadav Y, Singh AP, Pradhan R, Desai GR, Dey AB, Dey S (2018) Neuroprotection by ethanolic extract of Syzygium aromaticum in Alzheimer’s disease like pathology via maintaining oxidative balance through SIRT1 pathway. Exp Gerontol 110:277–283

16. Kim SH, Lu HF, Alano CC (2011) Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS one. 6(3):e14731

17. Cheng A, Yang Y, Zhou Y, Maharana C, Lu D, Peng W, Liu Y, Wan R, Marosi K, Misiaik M, Bohr VA (2016) Mitochondrial Sirt3 mediates adaptive responses of neurons to exercise and metabolic and excitatory challenges. Cell Metab 23(1):128–142

18. Lutz ML, Milenkovic I, Regelsberger G, Kovacs GG (2014) Distinct patterns of sirtuin expression during progression of Alzheimer’s disease. NeuroMol Med 16(2):405–414

19. Yin J, Han P, Song M, Nielsen M, Beach TG, Serrano GE, Liang WS, Caselli RJ, Shi J (2018) Amyloid-β increases tau by mediating sirtuin 3 in Alzheimer’s disease. Mol Neurobiol 55(11):8592–8601

20. Zeng L, Yang Y, Hu Y, Sun Y, Du Z, Xie Z, Zhou T, Kong W (2014) Age-related decrease in the mitochondrial sirtuin deacetylase Sirt3 expression associated with ROS accumulation in the auditory cortex of the mimetic aging rat model. PLoS One. 9(2):e88019

21. Weir HJ, Murray TK, Kehoe PG, Love S, Verdin EM, O’Neill MJ, Lane JD, Balthasar N (2012) CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer’s disease. PLoS one. 7(11):e48225

22. Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E (2013) Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α. Neurobiol Dis 51:72–81

23. Zhu H, Guo Q, Mattson MP (1999) Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res 842(1):224–229

24. Brida Y, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Smythe G, Sachdev P, Guillemin GI (2015) Differential expression of sirtuins in the aging rat brain. Front Cell Neurosci 9:1–16

25. Dutt Way V, Soga T, Parhar IS (2015) Aging and chronic administration of serotonin-selective reuptake inhibitor citalopram upregulate Sirt4 gene expression in the preoptic area of male mice. Front Genet 6:1–9

26. Schwer B, North BJ, Frye RA, Ott M, Verdin E (2002) The human silent information regulator (Sir) 2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide–dependent deacetylase. J Cell Biol 158(4):647–657

27. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL, Barrett JC, Chang HY (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452(7186):492–496

28. Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mcligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, D’Urso A (2013) SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. Mol Cell 51(4):454–468

29. Jung ES, Choi H, Song H, Hwang YJ, Kim A, Ryu H, Mook-Jung I (2016) p53-dependent SIRT6 expression protects Aβ42-induced DNA damage. Sci Rep 6(1):1–11

30. Kaluski S, Portillo M, Besnard A, Stein D, Eina M, Zhong L, Ueberham U, Arendt T, Mostoslavsky R, Sahay A, Toiber D (2017) Neuroprotective functions for the histone deacetylase SIRT6. Cell Rep 18(13):3052–3062

31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939

32. Pradhan R, Kumar R, Shekhar S, Rai N, Ambashtha A, Banerjee J, Pathak M, Dwivedi SN, Dey S, Dey AB (2017) Longevity and healthy ageing genes FOXO3A and SIRT3: serum protein marker and new road map to burst oxidative stress by Withania somnifera. Experimental Gerontology. 95:9–15

33. Han P, Tang Z, Yin J, Maaloul M, Beach TG, Reiman EM, Shi J (2014) Pituitary adenylyl cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging 35(9):2064–2071

34. Lattanzio F, Carboni L, Carretta D, Candeletti S, Romualdi P (2016) Treatment with the neurotoxic Aβ(25–35) peptide modulates the expression of neuroprotective factors Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y human neuroblastoma cells. Exp Toxicol Pathol 68(5):271–276

35. Weir HJ, Murray TK, Kehoe PG, Love S, Verdin EM, O’Neill MJ, Lane JD, Balthasar N (2012) CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer’s disease. PLoS one. 7(11):1–7

36. Rulten SL, Caldecott KW (2013) DNA strand break repair and neurodegeneration. DNA Repair 12(8):558–567

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.